Fly News Breaks for January 22, 2020
Jan 22, 2020 | 07:23 EDT
Novavax is exploring development of a Wuhan-coronavirus recombinant nanoparticle vaccine candidate, H.C. Wainwright analyst Vernon Bernardino tells investors in a research note. The company intends to develop a vaccine candidate from the genetic sequence of the coronavirus when it becomes available for research by the infectious disease community, which could be in the coming days, adds the analyst. He believes results from a vaccine lethal challenge study could be a positive catalyst later in Q1 for shares of Novavax. As such, Bernardino reiterates a Buy rating on Novavax with a $17 price target.
News For NVAX From the Last 2 Days
There are no results for your query NVAX